Humanin
Aliases: HN · HN analog S14G (HNG)
Last verified: 2026-09-23
The short version
A 24-aa mitochondrial peptide with cytoprotective action — levels decline with age and are higher in centenarians' offspring. Protects neurons from amyloid, improves insulin sensitivity. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical models of Alzheimer's, diabetes and cardiovascular disease; analogues (HNG) 1000× more potent. Status: preclinical. Not approved; research only.
Identity & type
- Molecular type
- peptide
- Origin
- A 24-aa mitochondrial peptide with cytoprotective action — levels decline with age and are higher in centenarians' offspring.
Mechanism of action
Acts via the trimeric CNTFR/WSX-1/gp130 receptor and FPRL1/2; anti-apoptotic (Bax inhibition), anti-inflammatory.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for Humanin. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
No human regimens; preclinical 1–10 mg/kg (analogues). Experiences are rare; individuals report better energy stability, but without consistent effects. Mostly of research interest.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Experiences are rare; individuals report better energy stability, but without consistent effects. Mostly of research interest.
Protocol — official vs community
Official / label
No approved product. Research has used analogues (e.g., HNG) in early human safety studies.
Duration: Study use only.
Mitochondrial-encoded cytoprotective peptide — the human work is still phase-1-adjacent.
Community (anecdotal)
1–2 mg SC daily appears in gray-market listings.
- Cycle:
- Undefined.
- Break:
- Undefined.
There is no community protocol worth the name — usage is a fraction of the interest.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical models of Alzheimer's, diabetes and cardiovascular disease; analogues (HNG) 1000× more potent.
Preclinical evidence
Preclinical models of Alzheimer's, diabetes and cardiovascular disease; analogues (HNG) 1000× more potent.
Known risks
- Unknown in humans.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.